ライフサイエンスコーパス: xenograft

1 recipitation sequencing of a patient-derived xenograft.

2 accomplished using a bovine versus a porcine xenograft.

3 ng PSMA(+) PC3 PIP and PSMA(-) PC3 flu flank xenografts.

4 egative patient-derived cell lines and mouse xenografts.

5 ith high uptake in lymphoid tissue and hPBMC xenografts.

6 CC cell xenografts and patient-derived tumor xenografts.

7 nation was ineffective against neuroblastoma xenografts.

8 1 antagonist treatment of melanoma and NSCLC xenografts.

9 xenografts compared to wild-type ATM control xenografts.

10 R, suppressing the growth of Ewing's sarcoma xenografts.

11 th as either subcutaneous or intraperitoneal xenografts.

12 ndent MYC expression and AML growth in mouse xenografts.

13 lastoma cell lines, primary human cells, and xenografts.

14 The tracer accumulates in CHL-GLP-1R xenografts.

15 (CRC) growth in cell culture and mouse tumor xenografts.

16 onse to anti-Cdk5 therapy in patient-derived xenografts.

17 remissions in 80% to 100% of NB and sarcoma xenografts.

18 cancer progression in GC cells and in mouse xenografts.

19 /c nude mice bearing subcutaneous CHL-GLP-1R xenografts.

20 thymic nude mice bearing subcutaneous MKN-45 xenografts.

21 sed cell growth both in culture and in mouse xenografts.

22 icroscopy of orthotopic sarcoma and melanoma xenografts.

23 line models and suppressing growth in tumor xenografts.

24 c bystander effects in delayed growth of DTC xenografts.

25 and angiogenesis in the human bladder cancer xenografts.

26 ivated the lytic cycle, including in Burkitt xenografts.

27 ty to T cell attack in vitro and in melanoma xenografts.

28 regional blood flow in the FME and LOX tumor xenografts.

29 Microtubule bundling was evident in PCa xenografts 2 to 3 days after docetaxel treatment but was

30 In xenografts, a significant tumor growth inhibition was se

31 inhibits castration-resistant PCa (CRPC) in xenograft and autochthonous PCa models.

32 These sEVs promote metastasis of xenograft and pancreatic tumors to lung in mice.

33 t HCC cell lines in vitro, and HCC tumors in xenograft and patient-derived xenograft mouse models.

34 Results from experiments with murine xenografts and 2D and 3D co-cultures of NHFs and PDAC ce

35 4)Cu or (89)Zr and evaluated in subcutaneous xenografts and adoptive cell transfer mouse models.

36 Patient-derived xenografts and cell lines with C-terminal truncations sh

37 Validation was done in patient-derived xenografts and human PC organoids.

38 metastatic disease burden in patient-derived xenografts and in mouse melanomas.

39 single-cell characterization of human tumor xenografts and in vivo CRISPR screens identified essenti

40 ns, we used the octapeptide to detect tumour xenografts and metastatic lesions, and to perform fluore

41 y arrested the growth of neratinib-resistant xenografts and organoids established from neratinib-resi

42 This study examined prostate cancer (PCa) xenografts and patient samples to identify in vivo mecha

43 ties in mouse models generated from MCC cell xenografts and patient-derived tumor xenografts.

44 hibitor pazopanib in MKN45 gastric carcinoma xenografts and the combination of tubulin-targeting agen

45 of firefly luciferase-expressing Hep3B tumor xenografts and the effects of the immune response during

46 S to four cell lines, to a cell-line-derived xenograft, and to normal and paired tumor/normal primary

47 rowth of breast cancer cells in vitro and in xenografts, and may be a novel approach for the safe and

48 +/- 23.7 %ID/g, respectively) in LNCaP tumor xenografts, and this peak was sustained up to 120 h afte

49 fectors HIF-1alpha and VEGF-A in cell lines, xenografts, and transgenic murine models.

50 In orthotopic xenograft animal model, TMPRSS2 overexpression promoted

51 nchmarks for clinical translation of cardiac xenografts appear to be within reach.

52 The zebrafish xenograft assay is ideal for personalized medicine.

53 otential of human cancer cell lines in mouse xenografts at scale.

54 o the periphery; following clearance of ATRT xenografts, B7-H3.BB.z-CAR T cells administered intracer

55 enhanced tumor uptake (29-46% IA/g at 4 h in xenografted BALB/c nude mice).

56 ic and orthotopic, including patient-derived xenograft, BC models.

57 and these yielded robust assessments across xenograft biological replicates.

58 ssay, and can arrest tumor growth in a mouse xenograft BT474 tumor model.

59 MIR1249KO xenograft BTC models showed tumor shrinkage after exposu

60 aneous or intraperitoneal human OVCAR-3 OvCa xenografts by dynamic PET/MRI, ex vivo biodistribution,

61 his system enabled intravital observation of xenografts by multiphoton microscopy, allowing us to vis

62 ibitor nilotinib in MDA-MB-468 breast cancer xenografts) caused changes in the tumor epithelial-mesen

63 de for using immunocompromised zebrafish for xenograft cell transplantation and credentials the model

64 Here, we describe the procedures for xenograft cell transplantation into the prkdc(-/-), il2r

65 In single dose studies with MIA PaCa2 xenografts, cohorts treated with ALDC1 had the highest a

66 promotes growth of ATM CRISPR knockout DLBCL xenografts compared to wild-type ATM control xenografts.

67 s strong inhibition of tumor growth in mouse xenografts, compared with MEK5 depletion or radiation al

68 In latency I BL xenografts, decitabine followed by EBV-CTLs results in T

69 tient-derived monosomal karyotype AML murine xenografts, decitabine treatment resulted in superior su

70 to induce an 80% tumor growth inhibition of xenografts derived from the enzalutamide-resistant (Enz-

71 on a panel of three patient-derived lymphoma xenografts derived from two patients with R/R B-NHL and

72 low and subsequent gefitinib accumulation in xenografted EGFR-mutant tumors.

73 Bevacizumab-resistant patient specimens and xenografts exhibited decreased vessel density and increa

74 Biophysical, cell-based, and murine xenograft experiments demonstrate that a synthetic zinc

75 The model was tested on seven xenograft experiments involving bevacizumab and three di

76 osis in vitro Likewise, in in vivo human GBM xenograft experiments with immunodeficient mice, mAb tre

77 ts of cancer mutations on tumor formation in xenograft experiments, and functional annotation based o

78 ative observations of metabolic gradients in xenograft GBM models.

79 Finally, C-B or C-I inhibited tumor xenograft growth in nude mice and decreased the expressi

80 ase inhibitor CB-839 preferentially inhibits xenograft growth of PIK3CA-mutant, but not wild-type (WT

81 icroglial chimeric mouse brains reveals that xenografted hPSC-derived microglia largely retain human

82 significantly regressed tumor growth in the xenograft human hepatocellular carcinoma mouse model.

83 atic cancer cells and the growth of a Panc-1 xenograft in SCID mice.

84 oxic (FME) and normoxic (LOX) human melanoma xenografts in a murine window chamber model.

85 wn inhibit the growth of patient-derived GBM xenografts in both zebrafish and mouse models.

86 Skin models, in culture and xenografts in immunodeficient mice, have potential for r

87 culture, and dramatically inhibited in vivo xenografts in mice, but had no effect on normal control

88 In tumor xenografts in mice, treatment with either BGJ398 or tram

89 ary and sufficient for growth of human tumor xenografts in mice.

90 t group 3 medulloblastoma and PFA ependymoma xenografts in mouse models.

91 ation, Y537S-ER, were used to generate tumor xenografts in ovariectomized female immunodeficient mice

92 a), which translated into improved growth of xenografts in the presence of 17beta-Estradiol.

93 acoustically visualized beta-cell insulinoma xenografts in vivo for the first time.

94 essive growth of BRAF(V600E)-mutant melanoma xenografts in vivo.

95 age differentiation in vitro and in tracheal xenografts in vivo.

96 s and alterations in metastatic tropism when xenografted into mice.

97 izumab therapy in two types of breast cancer xenografts (KPL-4 and MDA-MB-468).

98 nt of nude mice bearing FR-positive KB human xenografts led to cures in 100% of the test animals with

99 ds glioblastoma (GBM) and prostate carcinoma xenograft lesions in nude mice (eight and five-fold resp

100 tudies demonstrated that, when ectopic human xenograft LNCaP tumours in SCID mice were treated with S

101 breast cancer cells implanted as orthotopic xenografts, loss of G6PD modestly decreased primary site

102 preservation using either bovine or porcine xenograft material.

103 target-to-background ratio was achieved in a xenograft mice tumour model.

104 In PC-3 tumor-bearing xenograft mice, the CC-trapping, GRPR-targeted agonistic

105 esistant NSCLC cells (IC(50) = 77 nM) and in xenograft mice.

106 rranged AML patients in vitro and in vivo in xenograft mice.

107 d experimental lung metastasis in the HT1080 xenograft model and highlight the critical role of fibri

108 encing to characterize a patient-derived FLC xenograft model and identify therapeutic targets.

109 NBC tumor growth in vivo using an orthotopic xenograft model in immunocompromised mice.

110 r, BKM120, was tested in our patient-derived xenograft model leading to disease attenuation and prolo

111 In a xenograft model of acute myeloid leukemia, a single inje

112 graft mode of melanoma and a patient-derived xenograft model of colon cancer with a favorable safety

113 We have designed a xenograft model of human vasculature to address this iss

114 improved persistence and functionality in a xenograft model of pancreatic cancer.

115 ic efficacy of echinomycin, we established a xenograft model of TP53-mutated AML.

116 extended animal survival in patient-derived xenograft model systems in vivo more potently than singl

117 of 5-FU was shown in a colorectal zebrafish xenograft model that led to significant reductions in tu

118 A murine xenograft model using CD38-positive OPM2 multiple myelom

119 nation (Olaparib + BKM120) in the MDA-MB-468 xenograft model with a tumor growth inhibitory rate of 7

120 that induced growth delay in a neuroblastoma xenograft model with minimal toxicity.

121 (ABC) diffuse large B-cell lymphoma (DLBCL) xenograft model, but this compound suffered from a short

122 In a tumor xenograft model, GUS inhibition prevents intestinal toxi

123 elevant renal cell carcinoma patient-derived xenograft model, we use the (89)Zr-labeled anti-RTK anti

124 t in vivo tumor regression against the BT474 xenograft model.

125 genic markers and promotes tumor growth in a xenograft model.

126 -2 positive cervical cancer cell lines and a xenograft model.

127 nhibition of tumor progression in a leukemia xenograft model.

128 cell death and delays tumor growth in a PEL xenograft model.

129 cells and reduced prostate tumor growth in a xenograft model.

130 iated improved survival in an ovarian cancer xenograft model.

131 the efficient suppression of B lymphoma in a xenograft model.

132 pletion of PRH reduces CCA tumor growth in a xenograft model.

133 Humanised xenograft models allow for the analysis of human tissue

134 Patient derived xenograft models and cell cultures were successfully cre

135 t that, unexpectedly, in two different mouse xenograft models and four human and mouse cell lines we

136 s costimulated with 4-1BB or ICOS persist in xenograft models but those constructed with CD28 exhibit

137 and reduction of tumor burden in three mouse xenograft models driven by either wild-type or mutant RA

138 further evaluated in gastric and lung cancer xenograft models in mice.

139 on induced tumor regression in two HER2iR BC xenograft models in vivo.

140 ogenic differentiation in vitro and in mouse xenograft models in vivo.

141 combination against multiple patient-derived xenograft models makes it an excellent candidate for fur

142 ngle-cell RNA sequencing and patient-derived-xenograft models of breast cancer.

143 ap metabolites and lipids in patient-derived xenograft models of GBM.

144 tion in flank and orthotopic patient-derived xenograft models of GBM.

145 val advantages to mice in two distinct mouse xenograft models of PEL.

146 ty in mouse tumors and human patient-derived xenograft models of SCLC.

147 r functional studies in multiple culture and xenograft models reveal a coordinated role of GATA3 and

148 ibited strong monotherapy efficacy in cancer xenograft models that carry certain DNA damage repair de

149 ome program conserved across patient-derived-xenograft models that is highly predictive of poor survi

150 bioavailability in ovarian and colon cancer xenograft models when evaluated for dose-ranging efficac

151 In mouse xenograft models, METTL3 depletion significantly enhance

152 In cancer cell lines and xenograft models, mRNA and protein expressions of the ty

153 ful establishment of estrogen-sensitive HGSC xenograft models, OVSAHO and COV362, this work will enab

154 -mutated leukemia, including patient-derived xenograft models, through downregulation of key genes in

155 addition, using different CD127+ T-ALL/T-LBL xenograft models, we also reveal that residual tumor cel

156 ss diverse AML cell-line and patient-derived xenograft models, we find that acquisition of resistance

157 ate cancer cells in vitro and in vivo murine xenograft models.

158 ty and cell kill effect in PSMA-positive (+) xenograft models.

159 s) that manifest autonomous fibrogenicity in xenograft models.

160 n vitro and in vivo after transplantation in xenograft models.

161 resonance imaging (MRI) data from colorectal xenograft models.

162 ith cancer cell proliferation in culture and xenograft models.

163 leading to cancer cell death in vitro and in xenograft models.

164 r cell proliferation and metastasis in mouse xenograft models.

165 B and activated B cell-DLBCL cell lines and xenograft models.

166 ophagy in resistant melanoma cells and mouse xenograft models.

167 CL in vitro and inhibits ABC-DLBCL growth in xenograft models.

168 engagement, and tryptase inhibition in HMC1 xenograft models.

169 urden in vivo and improved survival in human xenograft models.

170 s used to test in vivo antitumor activity in xenografts models.

171 clinical verification of in vitro data using xenograft mouse model of MSCs confirmed the clinical rel

172 RNA using nanoparticles to the neuroblastoma xenograft mouse model showed around 15-20% ITCH silencin

173 ime that p190A is a tumor suppressor using a xenograft mouse model with carcinoma cells harboring def

174 isplays robust transduction in a human liver xenograft mouse model with expanded tropism for both mur

175 Using a xenograft mouse model, the function and stability of exp

176 mising activity against HL in vitro and in a xenograft mouse model.

177 rnover and modulate blood vessel networks in xenograft mouse models in vivo.

178 from cell line models, clinical samples and xenograft mouse models revealed mitogen-activated protei

179 Functional assessment in patient-derived xenograft mouse models validated the notion that MYC, YA

180 tance to targeted therapy in melanoma cells, xenograft mouse models, and patient samples.

181 , a miR-497 target, suppress tumor growth in xenograft mouse models, proposing the TAp63-miR-30c-2*/m

182 Using xenograft mouse models, we demonstrated that inhibition

183 ET neuroimaging radiopharmaceutical, in OvCa xenograft mouse models.

184 HCC tumors in xenograft and patient-derived xenograft mouse models.

185 or cell death and tumor growth inhibition in xenograft mouse models.

186 idated using primary AML patient samples and xenograft mouse models.

187 efficiently attenuates HCC tumorigenesis in xenograft mouse models.

188 olonged survival from 27 to 70 days in a GBM xenograft mouse resection model with no sign of tumour r

189 rosomal stability effectively suppressed the xenograft of MIA PaCa-2, a K-Ras(G12C)-expressing human

190 in transgenic TH-MYCN mice; (ii) orthotopic xenografts of a drug-resistant NB line SK-N-BE(2)C (muta

191 line SK-N-BE(2)C (mutated TP53); (iii) flank xenografts of a drug-resistant NB-PDX; and (iv) xenograf

192 d by oral administration of 27 in orthotopic xenografts of endocrine-resistant breast cancer in monot

193 ografts of a drug-resistant NB-PDX; and (iv) xenografts of Ewing sarcoma and rhabdomyosarcoma.

194 using an in vivo mouse model with orthotopic xenografts of HCC cells confirmed the in vitro data, and

195 d reduced growth of HCC cells in culture and xenografts of HCC tumors, suggesting that inhibition of

196 ignificantly suppresses tumor growth in nine xenograft or syngeneic models.

197 ility of the EFNA5 signalling pathway in GBM xenografts overexpressing Bmi1.

198 hantoms and followed by in vivo treatment of xenograft pancreatic cancer (BxPC-3) tumours in a murine

199 in syngeneic and patient-derived orthotopic xenograft (PDOX) mouse models of GBM.

200 ablished a unique patient-derived orthotopic xenograft (PDOX) nude mouse model of a highly aggressive

201 report the establishment of patient derived xenograft (PDX) and cell line models that reflect the ge

202 ore, when using intracranial patient-derived xenograft (PDX) approaches, it is advantageous to deploy

203 ) DNA repair-deficient HGSOC-patient-derived xenograft (PDX) in vivo.

204 Using molecularly classified patient-derived xenograft (PDX) lines, cultured in stem-cell conditions,

205 4 genomic signatures using a patient-derived xenograft (PDX) model treated with an FGFR4 inhibitor, w

206 e myelogenous leukemia (AML) patient-derived xenograft (PDX) models of acquired resistance to BCL-2 (

207 n genetically engineered and patient-derived xenograft (PDX) models of breast cancer.

208 mAbs) to CD3 have antileukemic properties in xenograft (PDX) models of CD3+ T-ALL, resulting in prolo

209 valuated against FR-positive patient derived xenograft (PDX) models of ovarian (ST070), endometrial (

210 Three patient-derived xenograft (PDX) models were grown in the flanks of NSG m

211 screening of 1,363 drugs in patient-derived xenograft (PDX) models.

212 ence of host tissues is with patient-derived xenograft (PDX) models.

213 s, and antitumor efficacy in patient-derived xenograft (PDX) SCLC models.

214 his study aimed to develop a patient-derived xenograft (PDX) tumor in mice by using a tumor from a pa

215 oteomics using breast cancer patient-derived xenograft (PDX) tumor samples.

216 drogenase (ALDH) activity of patient-derived xenograft (PDX) tumors, which was reversed by combinatio

217 BRAF(V600E)-driven melanoma patient-derived xenografts (PDX) and diminishes growth of NRAS(Q61R)-dri

218 Ex vivo models such as mouse patient-derived xenografts (PDX) and organoids are being developed to pr

219 embled a panel of orthotopic patient-derived xenografts (PDX) and subjected them to DNA sequencing, g

220 Patient-derived xenografts (PDX) are tumor-in-mouse models for cancer.

221 lone inhibited the growth of patient-derived xenografts (PDX), and SVC112 combined with radiation res

222 A panel of patient-derived ovarian cancer xenografts (PDX), similar in genetics and chemotherapy r

223 tumor samples including five patient-derived xenografts (PDX).

224 and bone metastasis-derived patient-derived xenografts (PDX).

225 ensitive and resistant patient-derived tumor xenografts (PDXs) indicate that PGM3 expression is speci

226 and acquired PARPi-resistant patient-derived xenografts (PDXs) models.

227 in HER2-mutant breast cancer patient-derived xenografts (PDXs) was also associated with TORC1 hyperac

228 d in a series of independent patient-derived xenografts (PDXs).

229 provided by transplantable, patient-derived xenografts (PDXs).

230 thotopic transplantation and patient-derived xenograft preclinical models, we defined clear functions

231 of the PARP inhibitor talazoparib in murine xenografts provides tumor suppression equivalent to a mo

232 istent survival of life-supporting pig heart xenograft recipients beyond 90 days was recently reporte

233 isotope tracing analysis in patient-derived xenografts revealed differences in nutrient handling bet

234 In vivo studies on mice xenografts revealed that the RNA nanoparticle predominan

235 tics in mice bearing receptor-positive tumor xenografts revealed up to 4-fold increased tumor uptake

236 clinical breast tumours and patient-derived xenograft samples that are resistant to endocrine therap

237 -231 breast cancer and FaDu head neck cancer xenografts show different pO(2) responses during each of

238 ever, small-animal PET studies in HT1080hFAP xenografts showed higher specific tumor uptake of [(18)F

239 duced in vivo tumor growth, as determined by xenograft studies in athymic nude mice.

240 In mouse xenograft studies, human stem cell-derived-interneuron p

241 crophage co-culture, migration and Zebrafish xenograft studies.

242 lso highly metastatic to lung and liver when xenografted subcutaneously in immune-deficient NSG mice.

243 estingly, NRP-1-depleted patient-derived GBM xenografts substantially prolonged survival in mice comp

244 lax in FP-RMS cell lines and patient-derived xenografts synergistically induced cell death and signif

245 cell lines, tumor organoids, chemoresistant xenografts, syngeneic tumors and PDX models.

246 ating cells in triple-negative breast cancer xenografts that rely on LEFTY1 for growth.

247 ir spatial distribution in porcine and mouse xenograft tissue.

248 alysis of prostate cancer plectin knock-down xenograft tissues.

249 tal microscopy of colorectal cancer organoid xenografts to investigate the cell of origin of metastas

250 , and when given orally effectively inhibits xenograft tumor growth and induces survivin loss in tumo

251 Furthermore, knockdown of PTPRF inhibited xenograft tumor growth in vivo and decreased the express

252 e cancer cell lines in vitro and for optimal xenograft tumor growth in vivo.

253 54, and GEM results in a potent reduction of xenograft tumor growth without any obvious side effects

254 verall, these data show that Rh-PPO inhibits xenograft tumor growth, supporting the strategy of using

255 A mouse xenograft tumor line was developed, and the tumor was su

256 educes 2-hydroxyglutarate levels in an mIDH1 xenograft tumor model.

257 l microscopy to quantify MT dynamics in live xenograft tumor models.

258 The method was evaluated in xenograft tumor samples using protease specific substrat

259 Treatment of HCC-PDX xenograft tumor-bearing mice with the c-Kit inhibitor im

260 ells (IC(50) = 17 nM) and in mice with H1975 xenograft tumor.

261 Athymic nude mice bearing EAC xenograft tumors (grown from OE-33 cells) were given int

262 Amiodarone markedly reduced the size of GBM xenograft tumors and displayed a strong anti-angiogenic

263 in construct potently inhibits the growth of xenograft tumors expressing the split counterpart.

264 tradiol, but only UM-SCC-12, not UM-SCC-11A, xenograft tumors grow larger in vivo in response to syst

265 In mice, xenograft tumors grown from AsPC-1 cells with ZIP4 knock

266 Both the patient primary tumor and the xenograft tumors had a significantly higher level of rec

267 pancreatic cancer cells, increased growth of xenograft tumors in mice, and increased expression of th

268 In vitro and in xenograft tumors in mice, targeting PRMT5 or pICln suppr

269 r specimen was undetectable after passage as xenograft tumors in mice.

270 on, induce autophagy, and slow the growth of xenograft tumors in mice.

271 protein in BE cells and slowed growth of EAC xenograft tumors in mice.

272 compounds, penfluridol, slowed the growth of xenograft tumors in the different mouse models, reducing

273 fied neuroblastoma cells and patient-derived xenograft tumors in vivo.

274 Treatment of xenograft tumors resulted in PD-L1-dependent tumor growt

275 there was a change in (64)Cu-ATSM signal in xenograft tumors smaller than 50 mg but not in larger tu

276 nin sensitizes triple-negative breast cancer xenograft tumors to chemotherapeutics and reduces metast

277 Subcutaneous xenograft tumors were grown in NSG mice from Panc1 cells

278 rall survival by controlling patient-derived xenograft tumors with greatly reduced host toxicities.

279 duction between different regions of CA20948 xenograft tumors, suggesting that different parts of the

280 detected in human original tumor tissues and xenograft tumors.

281 t, MITF.OE cells grew faster in vitro and as xenografted tumors compared to control cells.

282 s, while increased DRAIC represses growth of xenografted tumors.

283 d invasion in vitro, and were unable to form xenografted tumors.

284 d metastasis potential of HCC cell lines and xenografted tumors.

285 liferation of cancer cells and the growth of xenograft tumours.

286 tablished orthotopic GBM neurosphere-derived xenografts using advanced nanoparticle formulations redu

287 with a combination of osseous allograft and xenograft was used in 73 cases, 53 of which had preopera

288 nscript analysis of matching patient-derived xenografts we constructed dedicated classifiers for expe

289 otodynamic therapy in mice with subcutaneous xenografts, we observed a substantial and immediate occl

290 ype (WT) and ESR1-silenced LSCC cultures and xenografts were examined for 17beta-estradiol responsive

291 negative breast cancer and receptor-positive xenografts were implanted in athymic mice.

292 In our study, SU-DIPG-17 xenografts were more representative of human DIPG with a

293 COASY-knockdown xenografts were more vulnerable to radiation, showing de

294 CA20948 somatostatin receptor-positive tumor xenografts were treated with (177)Lu-DOTATATE or sham-tr

295 f gold nanoparticles within MCF7 tumor mouse xenografts which is followed by its photothermal remedia

296 both cultured cells and lung adenocarcinoma xenografts, while a subset had clinically relevant tumor

297 astasis, and reduces the survival of animals xenografted with Pten-NOLC1-expressing cancer cells.

298 human pancreatic ductal adenocarcinoma tumor xenografts with differing physiologic and metabolic char

299 an glioblastoma and describe patient-derived xenografts with species-conserved subtype-discriminating

300 models of TNBC, including a patient-derived xenograft, without inducing toxicity.